1. Home
  2. XBIO vs GOVX Comparison

XBIO vs GOVX Comparison

Compare XBIO & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.76

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$1.76

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
GOVX
Founded
N/A
2001
Country
United States
United States
Employees
2
17
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XBIO
GOVX
Price
$2.76
$1.76
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
N/A
$200.00
AVG Volume (30 Days)
23.1K
132.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.99
N/A
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$0.12
52 Week High
$13.93
$4.40

Technical Indicators

Market Signals
Indicator
XBIO
GOVX
Relative Strength Index (RSI) 63.54 45.66
Support Level $2.59 $0.55
Resistance Level $3.21 $4.40
Average True Range (ATR) 0.18 0.15
MACD 0.04 0.02
Stochastic Oscillator 79.64 51.00

Price Performance

Historical Comparison
XBIO
GOVX

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: